As the probiotic segment continues to trend upward, more companies are investing in well-designed clinical trials to support efficacy.
One area that has presented substantial learning opportunities, and has helped shape the future of probiotic clinical trials, is the study of antibiotic associated diarrhea (AAD) and probiotic intake.
In a new guest post for the International Probiotic Association (IPA), Josh Baisley, Associate Director of Clinical Trials at Nutrasource, discusses key learning points in this emerging field of study. These include guidance on how to:
- Understand potential confounding factors that could compromise a trial
- Define, measure and analyze appropriate study endpoints
- Choose an appropriate population for the health indication
- Better interpret and use a study's results